NASDAQ : BRVE
Braveheart Bio, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 21.19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.73B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Selling, General & Admin | 11.88M | 3.02M |
| Research & Development | 23.53M | 1.49M |
| Operating Expenses | 35.40M | 4.50M |
| Operating Income | -35.40M | -4.50M |
| Interest & Investment Income | 2.36M | 696.00K |
| Other Non Operating Income (Expenses) | 4.00K | 1.00K |
| EBT Excluding Unusual Items | -33.04M | -3.81M |
| Pretax Income | -94.84M | -66.05M |
| Net Income | -94.84M | -66.05M |
| Net Income to Common | -98.45M | -66.05M |
| Shares Outstanding (Basic) | 6.71M | 3.84M |
| Shares Outstanding (Diluted) | 6.71M | 3.84M |
| EPS (Basic) | -14.68 | -17.20 |
| EPS (Diluted) | -14.68 | -17.20 |
| EBIT | -35.40M | -4.50M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Cash & Equivalents | 122.83M | 89.16M |
| Cash & Short-Term Investments | 122.83M | 89.16M |
| Prepaid Expenses | 614.00K | 119.00K |
| Total Current Assets | 123.44M | 89.28M |
| Other Long-Term Assets | 70.00K | 70.00K |
| Total Assets | 126.96M | 89.35M |
| Accounts Payable | 2.67M | 1.06M |
| Accrued Expenses | 5.35M | 1.18M |
| Other Current Liabilities | 663.00K | 3.00M |
| Total Current Liabilities | 9.06M | 5.24M |
| Other Long-Term Liabilities | 86.00K | 91.00K |
| Total Liabilities | 9.34M | 5.33M |
| Common Stock | 1.00K | 3.00K |
| Additional Paid-In Capital | 177.00K | |
| Retained Earnings | -95.91M | -66.05M |
| Total Common Equity | -95.91M | -65.87M |
| Shareholders' Equity | 117.61M | 84.02M |
| Total Liabilities & Equity | 126.96M | 89.35M |
| Net Cash (Debt) | 122.26M | 89.16M |
| Net Cash Per Share | 18.23 | 23.22 |
| Filing Date Shares Outstanding | 81.63M | 6.69M |
| Total Common Shares Outstanding | 7.54M | 6.69M |
| Working Capital | 114.39M | 84.04M |
| Book Value Per Share | -12.73 | -9.85 |
| Tangible Book Value | -95.91M | -65.87M |
| Tangible Book Value Per Share | -12.73 | -9.85 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Net Income | -94.84M | -66.05M |
| Asset Writedown & Restructuring Costs | 61.80M | 62.24M |
| Stock-Based Compensation | 3.02M | 176.00K |
| Change in Accounts Payable | 1.83M | 896.00K |
| Change in Other Net Operating Assets | 4.04M | 722.00K |
| Operating Cash Flow | -24.15M | -2.01M |
| Sale (Purchase) of Intangibles | -36.57M | -33.57M |
| Investing Cash Flow | -36.60M | -33.57M |
| Issuance of Common Stock | 93.00K | 95.00K |
| Financing Cash Flow | 183.58M | 124.74M |
| Net Cash Flow | 122.83M | 89.16M |
| Change in Working Capital | 5.87M | 1.62M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Market Capitalization | 1.72B | |
| Enterprise Value | 1.60B | |
| Net Debt / Equity Ratio | -1.04 | -1.06 |
| Quick Ratio | 13.56 | 17.01 |
| Current Ratio | 13.63 | 17.03 |
| Return on Capital Employed (ROCE) | -30.00% | -5.40% |